Literature DB >> 29850182

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

Pascale Tomasini1,2, Laurent Greillier1,2, Arnaud Boyer1,2, Arnaud Jeanson1,2, Fabrice Barlesi1,2.   

Abstract

Entities:  

Year:  2018        PMID： 29850182      PMCID： PMC5949420          DOI： 10.21037/jtd.2018.04.61

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  13 in total

Review 1.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

2.  Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Authors:  Matthew D Hellmann; Naiyer A Rizvi; Jonathan W Goldman; Scott N Gettinger; Hossein Borghaei; Julie R Brahmer; Neal E Ready; David E Gerber; Laura Q Chow; Rosalyn A Juergens; Frances A Shepherd; Scott A Laurie; William J Geese; Shruti Agrawal; Tina C Young; Xuemei Li; Scott J Antonia
Journal:  Lancet Oncol       Date:  2016-12-05       Impact factor: 41.316

3.  Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

Authors:  Charles Butts; Mark A Socinski; Paul L Mitchell; Nick Thatcher; Libor Havel; Maciej Krzakowski; Sergiusz Nawrocki; Tudor-Eliade Ciuleanu; Lionel Bosquée; José Manuel Trigo; Alexander Spira; Lise Tremblay; Jan Nyman; Rodryg Ramlau; Gun Wickart-Johansson; Peter Ellis; Oleg Gladkov; José Rodrigues Pereira; Wilfried Ernst Erich Eberhardt; Christoph Helwig; Andreas Schröder; Frances A Shepherd
Journal:  Lancet Oncol       Date:  2013-12-09       Impact factor: 41.316

4.  Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy.

Authors:  Raphael Serre; Sebastien Benzekry; Laetitia Padovani; Christophe Meille; Nicolas André; Joseph Ciccolini; Fabrice Barlesi; Xavier Muracciole; Dominique Barbolosi
Journal:  Cancer Res       Date:  2016-06-14       Impact factor: 12.701

Review 5.  PD-L1 blockade for cancer treatment: MEDI4736.

Authors:  Ramy Ibrahim; Ross Stewart; Aiman Shalabi
Journal:  Semin Oncol       Date:  2015-02-25       Impact factor: 4.929

6.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

7.  Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis.

Authors:  Ping Zhang; Dong-Ming Su; Mei Liang; Jian Fu
Journal:  Mol Immunol       Date:  2007-10-24       Impact factor: 4.407

8.  A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.

Authors:  David Planchard; Takashi Yokoi; Michael J McCleod; Jürgen R Fischer; Young-Chul Kim; Marc Ballas; Kelvin Shi; Jean-Charles Soria
Journal:  Clin Lung Cancer       Date:  2016-03-17       Impact factor: 4.785

9.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

10.  B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells.

Authors:  Xin Liu; Xiaosheng Wu; Siyu Cao; Susan M Harrington; Peng Yin; Aaron S Mansfield; Haidong Dong
Journal:  Sci Rep       Date:  2016-11-08       Impact factor: 4.379
View more
  6 in total

1.  Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in stage III NSCLC patients undergoing maintenance immunotherapy.

Authors:  Yeona Cho; Yejin Kim; Ibrahim Chamseddine; Won Hee Lee; Hye Ryun Kim; Ik Jae Lee; Min Hee Hong; Byung Chul Cho; Chang Geol Lee; Seungryong Cho; Jin Sung Kim; Hong In Yoon; Clemens Grassberger
Journal:  Radiother Oncol       Date:  2022-01-13       Impact factor: 6.901

Review 2.  Application of PD-1 Blockade in Cancer Immunotherapy.

Authors:  Xiaomo Wu; Zhongkai Gu; Yang Chen; Borui Chen; Wei Chen; Liqiang Weng; Xiaolong Liu
Journal:  Comput Struct Biotechnol J       Date:  2019-05-23       Impact factor: 7.271

3.  A systematic analysis of immune genes and overall survival in cancer patients.

Authors:  Qian Wang; Pan Li; Weidong Wu
Journal:  BMC Cancer       Date:  2019-12-16       Impact factor: 4.430

4.  Durvalumab as Consolidation Therapy in Post-Multimodal Interventional Treatment for Patients with Advanced Solid Tumors: A Preliminary Study.

Authors:  Yuanming Li; Runqi Guo
Journal:  J Oncol       Date:  2022-03-15       Impact factor: 4.375

Review 5.  Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.

Authors:  Jia-Xin Li; Ju-Min Huang; Ze-Bo Jiang; Run-Ze Li; Ao Sun; Elaine Lai-Han Leung; Pei-Yu Yan
Journal:  Integr Cancer Ther       Date:  2019 Jan-Dec       Impact factor: 3.279

6.  The Correlation Between SPP1 and Immune Escape of EGFR Mutant Lung Adenocarcinoma Was Explored by Bioinformatics Analysis.

Authors:  Yi Zheng; Shiying Hao; Cheng Xiang; Yaguang Han; Yanhong Shang; Qiang Zhen; Yiyi Zhao; Miao Zhang; Yan Zhang
Journal:  Front Oncol       Date:  2021-06-10       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.